Approval · Notice of Compliance 23396 · 2020
RYBELSUS: Notice of Compliance 23396
Issued March 30, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23396
- Date
- March 30, 2020
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
Medicinal ingredients
- SEMAGLUTIDE 3 MG per TAB
- SEMAGLUTIDE 7 MG per TAB
- SEMAGLUTIDE 14 MG per TAB